Across TCGA pan-cancer cohorts, GUCA2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GUCA2A data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GUCA2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GUCA2A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, COAD, and SKCM are the cancer types where GUCA2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.038	0.553	<.001	12	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →
SKCM	DFS	Median	All	0.858	0.195	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: GUCA2A tumor-vs-normal RNA expression · all GUCA2A data types